BR112018068075A2 - inibidores de fosfatidilinositol 3-quinase gama - Google Patents
inibidores de fosfatidilinositol 3-quinase gamaInfo
- Publication number
- BR112018068075A2 BR112018068075A2 BR112018068075A BR112018068075A BR112018068075A2 BR 112018068075 A2 BR112018068075 A2 BR 112018068075A2 BR 112018068075 A BR112018068075 A BR 112018068075A BR 112018068075 A BR112018068075 A BR 112018068075A BR 112018068075 A2 BR112018068075 A2 BR 112018068075A2
- Authority
- BR
- Brazil
- Prior art keywords
- phosphatidylinositol
- kinase gamma
- gamma inhibitors
- compounds
- pi3k
- Prior art date
Links
- 108091007960 PI3Ks Proteins 0.000 title abstract 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title abstract 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662306328P | 2016-03-10 | 2016-03-10 | |
| PCT/EP2017/055552 WO2017153527A1 (en) | 2016-03-10 | 2017-03-09 | Novel inhibitors of phosphatidylinositol 3-kinase gamma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018068075A2 true BR112018068075A2 (pt) | 2019-01-08 |
Family
ID=58264542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018068075A BR112018068075A2 (pt) | 2016-03-10 | 2017-03-09 | inibidores de fosfatidilinositol 3-quinase gama |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10858355B2 (enExample) |
| EP (1) | EP3426652B1 (enExample) |
| JP (1) | JP6893520B2 (enExample) |
| KR (1) | KR20180117693A (enExample) |
| CN (1) | CN108779110B (enExample) |
| AR (1) | AR107840A1 (enExample) |
| AU (1) | AU2017229445B2 (enExample) |
| BR (1) | BR112018068075A2 (enExample) |
| CA (1) | CA3015893C (enExample) |
| EA (1) | EA036388B1 (enExample) |
| MX (1) | MX387125B (enExample) |
| TW (1) | TWI746525B (enExample) |
| WO (1) | WO2017153527A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11161838B2 (en) | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
| WO2020102216A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Substituted heterocyclic derivatives as pi3k inhibitors |
| WO2020102198A1 (en) * | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
| WO2020210379A1 (en) | 2019-04-10 | 2020-10-15 | Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. | Phosphatidylinositol 3-kinase inhibitors |
| AU2020288610A1 (en) | 2019-06-04 | 2022-01-27 | Arcus Biosciences, Inc. | 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds |
| WO2022017371A1 (zh) * | 2020-07-21 | 2022-01-27 | 中国医药研究开发中心有限公司 | 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途 |
| CN115611883B (zh) * | 2021-07-13 | 2025-03-28 | 生物岛实验室 | 一种双环结构的PI3Kα抑制剂及其制备方法和用途 |
| CN119768404A (zh) * | 2022-09-01 | 2025-04-04 | 上海海雁医药科技有限公司 | 杂芳基取代的吡啶并吡咯酮衍生物、其药物组合物及应用 |
| EP4585596A4 (en) * | 2022-09-09 | 2025-12-10 | Shanghai Yingli Pharm Co Ltd | Nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and uses thereof |
| CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
| EP4734987A1 (en) | 2023-06-30 | 2026-05-06 | Forschungsverbund Berlin E.V. | Thiazolo tetrahydrochinoline compounds as class ii phosphoinositide 3-kinase inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200613272A (en) * | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| US20080287469A1 (en) * | 2005-02-17 | 2008-11-20 | Diacovo Thomas G | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation |
| AU2007207743B2 (en) * | 2006-01-18 | 2010-07-08 | Amgen Inc. | Thiazole compounds as protein kinase B (PKB) inhibitors |
| JP2009535386A (ja) * | 2006-05-03 | 2009-10-01 | アストラゼネカ アクチボラグ | チアゾール誘導体および抗腫瘍剤としてのその使用 |
| EP1894931A1 (en) * | 2006-08-30 | 2008-03-05 | Cellzome Ag | Triazole derivatives as kinase inhibitors |
| US20110230472A1 (en) * | 2008-08-29 | 2011-09-22 | Shionogi & Co., Ltd. | Ring-fused azole derivative having pi3k-inhibiting activity |
| CA2752596A1 (en) * | 2009-02-17 | 2010-08-26 | Vertex Pharmaceuticals Incorporated | Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase |
| RU2573569C2 (ru) * | 2009-12-22 | 2016-01-20 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы фосфатидилинозитол-3-киназы на основе изоиндолинона |
| CN104379573A (zh) * | 2012-04-20 | 2015-02-25 | 艾伯维公司 | 异吲哚酮衍生物 |
| RU2675814C2 (ru) | 2013-09-25 | 2018-12-25 | Вертекс Фармасьютикалз Инкорпорейтед | 6,7-ДИГИДРО-5Н-ПИРРОЛО[3,4-b]ПИРИДИН-5-ОН, ПОЛЕЗНЫЙ В КАЧЕСТВЕ СЕЛЕКТИВНОГО ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ-ГАММА |
| AU2014391610B2 (en) | 2014-04-24 | 2018-01-25 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| KR20160145780A (ko) | 2014-04-24 | 2016-12-20 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체 |
| CA2945212A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
-
2017
- 2017-03-09 BR BR112018068075A patent/BR112018068075A2/pt not_active IP Right Cessation
- 2017-03-09 MX MX2018010894A patent/MX387125B/es unknown
- 2017-03-09 EP EP17709681.5A patent/EP3426652B1/en active Active
- 2017-03-09 EA EA201891931A patent/EA036388B1/ru not_active IP Right Cessation
- 2017-03-09 WO PCT/EP2017/055552 patent/WO2017153527A1/en not_active Ceased
- 2017-03-09 KR KR1020187028625A patent/KR20180117693A/ko not_active Abandoned
- 2017-03-09 JP JP2018547461A patent/JP6893520B2/ja not_active Expired - Fee Related
- 2017-03-09 TW TW106107711A patent/TWI746525B/zh not_active IP Right Cessation
- 2017-03-09 CA CA3015893A patent/CA3015893C/en active Active
- 2017-03-09 CN CN201780014898.XA patent/CN108779110B/zh not_active Expired - Fee Related
- 2017-03-09 AU AU2017229445A patent/AU2017229445B2/en not_active Ceased
- 2017-03-09 US US16/082,880 patent/US10858355B2/en not_active Expired - Fee Related
- 2017-03-09 AR ARP170100589A patent/AR107840A1/es unknown
-
2020
- 2020-11-04 US US17/088,689 patent/US20210047312A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA201891931A1 (ru) | 2019-04-30 |
| EA036388B1 (ru) | 2020-11-03 |
| TW201808945A (zh) | 2018-03-16 |
| WO2017153527A1 (en) | 2017-09-14 |
| US10858355B2 (en) | 2020-12-08 |
| AU2017229445B2 (en) | 2019-07-11 |
| US20210047312A1 (en) | 2021-02-18 |
| JP6893520B2 (ja) | 2021-06-23 |
| JP2019507788A (ja) | 2019-03-22 |
| KR20180117693A (ko) | 2018-10-29 |
| AR107840A1 (es) | 2018-06-13 |
| MX2018010894A (es) | 2018-11-09 |
| MX387125B (es) | 2025-03-18 |
| US20200299289A1 (en) | 2020-09-24 |
| EP3426652A1 (en) | 2019-01-16 |
| CA3015893C (en) | 2021-11-09 |
| CN108779110A (zh) | 2018-11-09 |
| CA3015893A1 (en) | 2017-09-14 |
| AU2017229445A1 (en) | 2018-10-25 |
| CN108779110B (zh) | 2021-10-29 |
| TWI746525B (zh) | 2021-11-21 |
| EP3426652B1 (en) | 2021-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018010894A (es) | Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma. | |
| BR112019004719A2 (pt) | derivados de 5-[2-(piridin-2-ilamino)-1,3-tiazol-5-il]-2,3-di-hidro-1h-isoindol-1-ona e seu uso como inibidores duais de fosfatidilinositol 3-quinase delta e gama | |
| CY1120049T1 (el) | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i | |
| BR112015020787A2 (pt) | inibidores quinazolínicos de formas mutantes ativantes do receptor do fator de crescimento epidérmico | |
| BR112016015818A2 (pt) | Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1 | |
| BR112015028501A2 (pt) | derivados de bipirazol como inibidores de jak | |
| BR112019024322A2 (pt) | Compostos e composições terapêuticos e métodos de uso dos mesmos | |
| BR112016015983A2 (pt) | Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica | |
| BR112015016793A2 (pt) | compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim | |
| BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
| BR112019012217A2 (pt) | compostos de amino-triazolopiridina e seu uso no tratamento de câncer | |
| BR112015019412A8 (pt) | inibidores de bace1, seus usos, e composição farmacêutica | |
| BR112017004173A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica. | |
| AR104068A1 (es) | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer | |
| BR112017021522A2 (pt) | ?composto, composição farmacêutica, uso de composto e método de tratamento de distúrbios? | |
| BR112017001160A2 (pt) | [1,2,4]triazol[4,3-b]piridazinas para uso no tratamento de doenças proliferativas | |
| BR112022013227A2 (pt) | Inibidores de btk | |
| BR112019000603A2 (pt) | composto, composição farmacêutica, método para o tratamento de doenças e uso do composto | |
| BR112018068532A2 (pt) | combinações de inibidores de lsd1 para o tratamento de malignidades hematológicas | |
| EA202090672A2 (ru) | ТИАЗОЛКАРБОКСАМИДЫ И ПИРИДИНКАРБОКСАМИДЫ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Pim-КИНАЗЫ | |
| BR112017024933A8 (pt) | Alvocidib produce com a bioavailabilidade aumentada | |
| BR112017005050A2 (pt) | composição farmacêutica, nebulizador e método de tratamento ou prevenção de doenças |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2713 DE 03-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |